Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 14, 2026, 2:01 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2353–2376 of 6,233 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Part 1 Clear all

Conditions: Huntington Disease
Interventions: SAGE-718; Drug
Lead sponsor: Supernus Pharmaceuticals, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 6 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019
U.S. locations: 2
States / cities: Long Beach, California • Marlton, New Jersey

Conditions: Acute Myeloid Leukemia (AML)
Interventions: Venetoclax, Azacitidine; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 112 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2026
U.S. locations: 27
States / cities: Mobile, Alabama • Fountain Valley, California • Los Angeles, California + 21 more

Conditions: HIV
Interventions: Raltegravir; Drug
Lead sponsor: University of Nebraska; Other
Eligibility: 19 Years and older
Enrollment: 12 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 1
States / cities: Omaha, Nebraska

Conditions: Advanced Solid Tumor
Interventions: DS-1471a; Drug
Lead sponsor: Daiichi Sankyo Co., Ltd.; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 2
States / cities: Sarasota, Florida • Milwaukee, Wisconsin

Conditions: Duchenne Muscular Dystrophy
Interventions: RGX-202; Genetic
Lead sponsor: REGENXBIO Inc.; Industry
Eligibility: 1 Year and older · Male only
Enrollment: 65 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 19
States / cities: Little Rock, Arkansas • Orange, California • Palo Alto, California + 16 more

Conditions: Community-acquired Pneumonia, Bacterial Pneumonia
Interventions: CMTX-101, Placebo; Drug
Lead sponsor: Clarametyx Biosciences, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 28 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2022 – 2024
U.S. locations: 8
States / cities: Augusta, Georgia • Idaho Falls, Idaho • Louisville, Kentucky + 5 more

Conditions: Muscular Dystrophies
Interventions: GSK3439171A, Placebo; Drug
Lead sponsor: GlaxoSmithKline; Industry
Eligibility: 18 Years to 65 Years · Male only
Enrollment: 66 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Breast Cancer, Lung Cancer, Prostate Cancer
Interventions: focus groups; Behavioral
Lead sponsor: Memorial Sloan Kettering Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 67 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2013
U.S. locations: 1
States / cities: New York, New York

Conditions: High-Grade Glioma
Interventions: XRD-0394, Radiation Therapy, Surgical Resection; Drug · Radiation · Procedure
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years and older
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2031
U.S. locations: 1
States / cities: New York, New York

Conditions: Alcohol-Related Disorders, Substance-Related Disorders, Mental Health, Reproductive Health, Sexual Health, Sexually Transmitted Diseases, Contraception, Maternal Health, Pregnancy, Women's Health
Interventions: Screening, Brief Intervention, and Referral to Treatment (SBIRT); Behavioral
Lead sponsor: Emory University; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 4
States / cities: Boston, Massachusetts • Marlborough, Massachusetts • Springfield, Massachusetts + 1 more

Conditions: DM1, Myotonic Dystrophy 1, Myotonic Dystrophy, Myotonic Dystrophy Type 1 (DM1), Dystrophy Myotonic, Myotonic Disorders, Steinert Disease, Myotonic Muscular Dystrophy
Interventions: AOC 1001, Placebo; Drug
Lead sponsor: Avidity Biosciences, Inc.; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 39 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2023
U.S. locations: 8
States / cities: Los Angeles, California • Palo Alto, California • Denver, Colorado + 5 more

Conditions: HIV
Interventions: Raltegravir; Drug
Lead sponsor: University of Washington; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 10 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: Started 2011
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: Hepatitis C
Interventions: Placebo, TMC435, Peginterferon alpha-2a (PegIFN alpha-2a), Ribavirin (RBV); Drug
Lead sponsor: Janssen R&D Ireland; Industry
Eligibility: 18 Years and older
Enrollment: 395 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2013
U.S. locations: 22
States / cities: Dothan, Alabama • Hoover, Alabama • Phoenix, Arizona + 19 more

Conditions: Coronavirus Disease (COVID-19)
Interventions: V590, Placebo; Biological · Other
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 232 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2020 – 2021
U.S. locations: 7
States / cities: Tempe, Arizona • Miami, Florida • South Miami, Florida + 4 more

Conditions: Multiple Sclerosis
Interventions: tDCS Administration during MRI, Remotely-supervised Daily tDCS Administration, Optional 15 minutes of imaging + simultaneous tDCS up to 4.0mA; Device
Lead sponsor: NYU Langone Health; Other
Eligibility: 18 Years to 79 Years
Enrollment: 73 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Cystic Fibrosis
Interventions: VX-581, Placebo, D-IVA, TEZ, ELX/TEZ/IVA, IVA; Drug
Lead sponsor: Vertex Pharmaceuticals Incorporated; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Overland Park, Kansas

Conditions: Leukemia, Lymphocytic, Chronic, B-Cell, Lymphoma, Large B-Cell, Diffuse, Lymphoma, Follicular, Lymphoma, Mantle-Cell, Precursor Cell Lymphoblastic Leukemia-Lymphoma
Interventions: Part 1 (Dose Escalation): Duvortuxizumab, Part 2 (Dose Expansion): Duvortuxizumab; Drug
Lead sponsor: Janssen Research & Development, LLC; Industry
Eligibility: 18 Years and older
Enrollment: 59 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2018
U.S. locations: 6
States / cities: Detroit, Michigan • New York, New York • Columbus, Ohio + 3 more

Conditions: Rhabdomyosarcoma
Interventions: Vincristine, Dactinomycin, Cyclophosphamide, Surgical Resection, Proton beam radiation or external beam radiation or brachytherapy, Liposomal irinotecan, Vinorelbine, Temozolomide, Filgrastim, peg-filgrastim; Drug · Procedure
Lead sponsor: St. Jude Children's Research Hospital; Other
Eligibility: Up to 22 Years
Enrollment: 135 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2037
U.S. locations: 3
States / cities: Palo Alto, California • Memphis, Tennessee • Fort Worth, Texas

Conditions: Healthy Volunteers
Interventions: INS1007, Placebo; Drug
Lead sponsor: Insmed Incorporated; Industry
Eligibility: 18 Years to 50 Years
Enrollment: 82 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019
U.S. locations: 1
States / cities: Glendale, California

Conditions: Neoplasms
Interventions: MK-4830, Pembrolizumab, Carboplatin, Pemetrexed, Lenvatinib, Paclitaxel, Cisplatin, MK-4830A; Drug · Biological
Lead sponsor: Merck Sharp & Dohme LLC; Industry
Eligibility: 18 Years and older
Enrollment: 470 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 9
States / cities: San Francisco, California • Detroit, Michigan • St Louis, Missouri + 6 more

Conditions: Multiple Sclerosis, Pain
Interventions: Cognitive Behavioral Therapy (CBT) +Hypnosis (HYP), Cognitive Behavioral Therapy (CBT), Self-Hypnosis Training (HYP), Education Control (CONT); Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: Seattle, Washington

Conditions: B-cell Acute Lymphoblastic Leukemia
Interventions: UCART22, CLLS52; Biological
Lead sponsor: Cellectis S.A.; Industry
Eligibility: 12 Years to 50 Years
Enrollment: 45 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2027
U.S. locations: 15
States / cities: Birmingham, Alabama • Los Angeles, California • San Francisco, California + 12 more

Conditions: Actinic Keratosis
Interventions: LEO 43204, Placebo; Drug
Lead sponsor: LEO Pharma; Industry
Eligibility: 18 Years and older
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 1
States / cities: Snellville, Georgia

Conditions: Attention Deficit Hyperactivity Disorder
Interventions: Meta Quest 3 VR Headset with noise cancelling headphones; Behavioral
Lead sponsor: Rutgers, The State University of New Jersey; Other
Eligibility: 18 Years to 25 Years
Enrollment: 252 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2030
U.S. locations: 2
States / cities: Baton Rouge, Louisiana • New Brunswick, New Jersey

Search by objective public record fields.

A Study to Evaluate Safety, Tolerability, and Pharmacokinetics of SAGE-718 Oral Solution in Patients With Huntington's Disease - Part B

A Study of Oral Venetoclax Tablets and Oral Azacitidine as Maintenance Therapy in Adult Participants With Acute Myeloid Leukemia in First Remission After Conventional Chemotherapy

Measurement of Plasma and Intracellular Concentrations of Raltegravir

A Study of DS-1471a In Subjects With Advanced Solid Tumors

AFFINITY DUCHENNE: RGX-202 Gene Therapy in Participants With Duchenne Muscular Dystrophy (DMD)

A 2-Part First-in-Human Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of CMTX-101

First Time in Human (FTIH) Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Single and Repeat Doses of GSK3439171A in Healthy Subjects and to Assess Food Effect

Development of a Clinical Trial Specific Question Prompt List

Concurrent XRD-0394 With Radiation Therapy for High Grade Gliomas

Improving Alcohol and Substance Use Care Access, Outcome, Equity During the Reproductive Years

Study of AOC 1001 in Adult Myotonic Dystrophy Type 1 (DM1) Patients

Levels of Raltegravir in the Female Genital Tissue

An Efficacy, Safety, and Tolerability Study of TMC435 in Treatment-naive, Genotype 1 Hepatitis C-infected Patients

Dose Ranging Trial to Assess Safety and Immunogenicity of V590 (COVID-19 Vaccine) in Healthy Adults (V590-001)

Assessment of tDCS-Induced Neuronal Responses in Multiple Sclerosis (MS) With Advanced MRI

Evaluation of VX-581 in Healthy Participants and in Participants With Cystic Fibrosis

A Dose Escalation Study of Duvortuxizumab in Participants With Relapsed or Refractory B-cell Malignancies

Treatment of Newly Diagnosed Rhabdomyosarcoma Using Molecular Risk Stratification and Liposomal Irinotecan Based Therapy in Children With Intermediate and High Risk Disease

A Study of the Safety, Pharmacokinetics, and Pharmacodynamics of INS1007 in Healthy Japanese and Caucasian Participants

Study of MK-4830 as Monotherapy and in Combination With Pembrolizumab (MK-3475) in Participants With Advanced Solid Tumors (MK-4830-001)

Management of Pain in Persons With Multiple Sclerosis

Phase 1/2 Study of UCART22 in Patients With Relapsed or Refractory CD22+ B-cell Acute Lymphoblastic Leukemia (BALLI-01)

Safety and Efficacy of Doses of LEO 43204 Once Daily for Two Consecutive Days on Full Balding Scalp in Subjects With Actinic Keratosis

R61/33 - VR Study Phase 4